Long acting GLP-1 receptor agonist (injectable)
Liraglutide 0.6 mg subcutaneous once daily
LIRA_SC_0p6MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-1.12 to -0.46) | 0.41 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.99 (-1.32 to -0.66) | 0.94 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.14 (-0.64 to 2.93) | 0.21 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.08 (-1.02 to 1.15) | 0.40 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.62 (1.03 to 5.81) | 0.29 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.30 (0.00 to 12.51) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.59 (1.02 to 2.44) | 0.26 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.79 (1.02 to 3.11) | 0.64 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.74 (1.35 to 5.44) | 0.49 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.30 (0.82 to 2.03) | 0.60 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.47 (0.55 to 3.72) | 0.54 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.75 (0.04 to 11.76) | 0.50 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.20 (-0.85 to 0.62) | 0.56 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.07 (0.60 to 1.94) | 0.44 |
| Type 1 diabetes | Nausea | longest follow-up | Placebo | HR 2.54 (1.58 to 3.99) | 0.65 |
| Type 1 diabetes | Vomiting | longest follow-up | Placebo | HR 1.54 (0.78 to 3.07) | 0.68 |
| Type 1 diabetes | Diarrhea | longest follow-up | Placebo | HR 0.96 (0.54 to 1.67) | 0.82 |
| Type 1 diabetes | Constipation | longest follow-up | Placebo | HR 1.16 (0.49 to 2.67) | 0.76 |
Trials
- ADJUNCT TWO™A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial2014 · 835 randomized · 26 weeks
- S0030412014 · 35 randomized · 2 weeks
- ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial2013 · 1,398 randomized · 52 weeks
- NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes2006 · 267 randomized · 52 weeks
- LEAD-2Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes2006 · 1,091 randomized · 26 weeks